NCT05873608 Communication Issues in Patient and Provider Discussions of Immunotherapy
| NCT ID | NCT05873608 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emory University |
| Condition | Hematopoietic and Lymphoid System Neoplasm |
| Study Type | INTERVENTIONAL |
| Enrollment | 125 participants |
| Start Date | 2016-10-06 |
| Primary Completion | 2027-09-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 125 participants in total. It began in 2016-10-06 with a primary completion date of 2027-09-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trials studies communication issues in patient and provider discussions about immunotherapy. The goal of this study is to describe where patients have heard about immunotherapy, what the participants understand about it, how physicians and other healthcare workers describe immunotherapy, and how educational videos may support patient knowledge about immunotherapy.
Eligibility Criteria
Inclusion Criteria: * AIMS 1-3: All patients and providers who may have a discussion about immunotherapy at the Winship Cancer Institute * AIM 4: Any cancer patient
Contact & Investigator
Rebecca Pentz, PhD
PRINCIPAL INVESTIGATOR
Emory University Hospital/Winship Cancer Institute
Frequently Asked Questions
Who can join the NCT05873608 clinical trial?
This trial is open to participants of all sexes, studying Hematopoietic and Lymphoid System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05873608 currently recruiting?
Yes, NCT05873608 is actively recruiting participants. Contact the research team at rpentz@emory.edu for enrollment information.
Where is the NCT05873608 trial being conducted?
This trial is being conducted at Atlanta, United States, Decatur, United States.
Who is sponsoring the NCT05873608 clinical trial?
NCT05873608 is sponsored by Emory University. The principal investigator is Rebecca Pentz, PhD at Emory University Hospital/Winship Cancer Institute. The trial plans to enroll 125 participants.